Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a report released on Thursday.
Several other research analysts have also recently commented on ALNY. Scotiabank lowered their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating for the company in a report on Friday, February 14th. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a "neutral" rating in a report on Tuesday. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Piper Sandler restated an "overweight" rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $304.26.
Get Our Latest Stock Analysis on Alnylam Pharmaceuticals
NASDAQ ALNY traded down $0.68 on Thursday, hitting $241.75. 475,338 shares of the stock were exchanged, compared to its average volume of 789,148. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a market cap of $31.30 billion, a PE ratio of -111.41 and a beta of 0.39. The company has a 50-day moving average price of $254.86 and a 200-day moving average price of $260.57.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.
In other news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 over the last 90 days. Company insiders own 1.50% of the company's stock.
Hedge funds have recently made changes to their positions in the stock. Huntington National Bank grew its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $28,000. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. Finally, Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.